NCT04690920View on ClinicalTrials.gov

Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions
Corona Virus Disease 2019 (COVID-19)
Interventions
DRUG

Tocilizumab

Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Trial Locations (1)

54000

The University of Lahore, Lahore

All Listed Sponsors
lead

University of Lahore

OTHER

NCT04690920 - Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins | Biotech Hunter | Biotech Hunter